A research and development overview of Fingolimod
NIU Jun-xing
HU Li-hong
Abstract：Fingolimod(FTY720),a novel immunomodulator agent,is developed from ISP - I,which is a secondary metabolites of fungi. It was approved by FDA in 2012 for the treatment of autoimmune disease multiple sclerosis. Unlike the traditional immunosup-pressive agents,fingolimod exerts immunosuppressive and immunoregulatory functions mainly through interaction with shhingosine - 1 -phosphate(S1P)receptors on the cell surface without affecting activation and proliferation of lymphocyhtes. This article briefly reviewed the development process of fingolimod,elaborate the structural optimization and transformation,in order to provide experience for chemi-cal rsearch.
Keywords：FinglimodISP - IMultiple SclerosisImmunomodulator
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 683-687,698 )